scholarly journals Thrombosis and Anticoagulant Therapy Among Pediatric Cancer Patients: Real-Life Data

Cureus ◽  
2021 ◽  
Author(s):  
Hasan Hashem ◽  
Momen Zeineddin ◽  
Rayan Bater ◽  
Nisreen Amayiri ◽  
Wiam Al-Qasem ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Anticoagulant Therapy ◽  
Pediatric Cancer ◽  
Real Life ◽  
Life Data ◽  
Real Life Data ◽  
Pediatric Cancer Patients

scholarly journals Nivolumab in Heavily Pretreated Metastatic Gastric Cancer Patients: Real-Life Data from a Western Population

2020 ◽  
Vol Volume 13 ◽  
pp. 867-876 ◽  
Author(s):  
Angelica Petrillo ◽  
Giuseppe Tirino ◽  
Federica Zito Marino ◽  
Luca Pompella ◽  
Rosalaura Sabetta ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Real Life ◽  
Metastatic Gastric Cancer ◽  
Western Population ◽  
Life Data ◽  
Real Life Data ◽  
Heavily Pretreated ◽  
Gastric Cancer Patients

scholarly journals Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real‐life data

2020 ◽  
Vol 148 (2) ◽  
pp. 296-306
Author(s):  
Patricia A. H. Hamers ◽  
Marloes A. G. Elferink ◽  
Rebecca K. Stellato ◽  
Cornelis J. A. Punt ◽  
Anne M. May ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Survival Time ◽  
Cancer Patients ◽  
Real Life ◽  
Life Data ◽  
Real Life Data ◽  
Colorectal Cancer Patients ◽  
Multiple Scenarios

scholarly journals Antifungal Combination Therapy in Children with Cancer—A 4-Year Analysis of Real-Life Data of Two Major Pediatric Cancer Centers

2021 ◽  
Vol 7 (8) ◽  
pp. 604
Author(s):  
Stefan Schöning ◽  
Konrad Bochennek ◽  
Kathrin Gordon ◽  
Andreas H. Groll ◽  
Thomas Lehrnbecher
Keyword(s):  
Combination Therapy ◽  
Pediatric Cancer ◽  
Hematopoietic Cell Transplantation ◽  
Real Life ◽  
Invasive Fungal Disease ◽  
Fungal Disease ◽  
Clinical Deterioration ◽  
Cancer Centers ◽  
Life Data ◽  
Real Life Data

Clinical data on antifungal combination therapy are limited, in particular in the pediatric setting. We analyzed real-life data collected in two major pediatric cancer centers over a period of 4 years. Patients were identified in an observational study on children with acute leukemia and lymphoma or undergoing hematopoietic cell transplantation. Out of 438 patients, 19 patients received 21 episodes of antifungal combination therapy. Therapy was mostly started for sepsis (n = 5) or clinical deterioration with pulmonary infiltrates (n = 10), and less often for periorbital swelling with suspected mold infection (n = 2), clinical deterioration and new skin lesions, secondary antifungal prophylaxis, a persistently elevated galactomannan index, or as pre-emptive treatment (n = 1 each). Diagnostics revealed proven, probable, and possible invasive fungal disease in two, seven and four episodes, respectively. Most regimens included caspofungin (n = 19), and treatment was initiated as first line therapy in 10 episodes. The median duration was 13 days (4–46 days). Nine of the 13 patients with proven, probable, or possible invasive fungal disease survived, which was comparable to patients receiving antifungal monotherapy. Our analysis demonstrates that combination therapy has mainly been prescribed in selected immunocompromised patients with clinical deterioration due to suspected invasive fungal disease or those with sepsis, and is well tolerated. Future studies need to better characterize clinical settings in which patients may benefit from antifungal combination therapy.

PH-0272 Prospective quality of life in 682 lung cancer patients treated with radiotherapy: real life data

2021 ◽  
Vol 161 ◽  
pp. S181-S182
Author(s):  
M. Nies ◽  
R. Wijsman ◽  
O. Chouvalova ◽  
F.J. Ubbels ◽  
H.J. Elzinga ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Cancer Patients ◽  
Real Life ◽  
Lung Cancer Patients ◽  
Life Data ◽  
Real Life Data
Sign in / Sign up

Export Citation Format

Share Document